Live donor liver transplantation for antitubercular drug-induced acute liver failure

被引：3

作者：

Bavikatte A.P. ^{[1
]}

Sudhindran S. ^{[1
]}

Dhar P. ^{[1
]}

Sudheer O.V. ^{[1
]}

Unnikrishnan G. ^{[1
]}

Balakrishnan D. ^{[1
]}

Menon R.N. ^{[1
]}

机构：

[1] Department of Gastrointestinal and Multiviceral Transplant Surgery, Amrita Institute of Medical Sciences and Research Centre, Ponnekkara, Kochi

来源：

Indian Journal of Gastroenterology | 2017年 / 36卷 / 1期

关键词：

Acute liver failure; Antitubercular therapy; Live donor liver transplantation;

D O I：

10.1007/s12664-016-0725-1

中图分类号：

学科分类号：

摘要：

Antitubercular therapy (ATT)-induced hepatotoxicity is often over looked and active tuberculosis is considered a contraindication for liver transplantation, however it might be the only lifesaving option to certain patients of acute liver failure (ALF) due to ATT. We have assessed the outcome of live donor liver transplantation in ATT-induced ALF. A retrospective analysis of all the cases of ALF that underwent liver transplantation from 2006 to 2014 at the Amrita Institute of Medical Sciences was done. A total of seven (7.7%) patients with ATT-induced ALF who had underwent live donor liver transplantation were included in the study. Out of seven patients, three (42.8%) had established diagnosis of tuberculosis and the remaining (58.2%) patients were started on ATT empirically. The median duration of ATT intake was 2 months. All the patients underwent live donor liver transplant as they met King’s College criteria, and their model for end-stage liver disease score was above 35 on admission, receiving graft from first degree relatives. Histopathology of explant liver showed pan acinar necrosis. Restarting of ATT after transplant was individualized. It was restarted only in two (28%) patients with prior sputum-positive pulmonary tuberculosis after a median time of 27 days after transplant. ATT was not restarted in rest of the (72%) patients. Postoperative mortality was seen in two (28%) patients due to conditions that masquerade the ATT-induced acute liver failure. The overall survival rate was 71.4% with a median follow up of 22 months. Live donor-related transplantation is feasible option in ATT-induced acute liver failure. Restarting of ATT post liver transplant is feasible and should be individualized along with frequent monitoring of immunosuppressant levels; however, if the primary diagnosis of tuberculosis was empirical, reintroduction of ATT can be omitted. © 2017, Indian Society of Gastroenterology.

引用

页码：56 / 61

页数：5

共 15 条

[1]

Training module for Community pharmacists. Document. New Delhi: Ministry of Health and Family Welfare, Central TB Division, (2013)

[2]

Devarbhavi H., Antituberculous drug-induced liver injury: current perspective, Trop Gastroenterol, 32, pp. 167-174, (2011)

[3]

Kumar R., Shalimar, Bhatia V., Et al., Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome, Hepatology, 51, pp. 1665-1674, (2010)

[4]

Abera W., Cheneke W., Abebe G., Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: a cohort study, Int J Mycobacteriol, 5, pp. 14-20, (2016)

[5]

Polson J., Lee W.M., American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure, Hepatology, 41, pp. 1179-1197, (2005)

[6]

Ferenci P., Lockwood A., Mullen K., Tartar R., Weissenborn K., Biel A.T., Hepatic encephalopathy-definition, nomenclature, diagnosis and quantification: final report of the working party at the 11th World Congress Gastroenterology, Vienna, 1998, Hepatology, 35, pp. 716-721, (2002)

[7]

Adhvaryu M.R., Reddy N., Vakharia B.C., Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach, World J Gastroenterol, 14, pp. 4753-4762, (2008)

[8]

Parkash O., Mumtaz K., Hamid S., Ali Shah S.H., Wasim Jafri S.M., MELD score: utility and comparison with King’s College criteria in non-acetaminophen acute liver failure, J Coll Physicians Surg Pak, 22, pp. 492-496, (2012)

[9]

Russo M.W., Galanko J.A., Shrestha R., Fried M.W., Watkins P., Liver transplantation for acute liver failure from drug-induced liver injury in the United States, Liver Transpl, 10, pp. 1018-1023, (2004)

[10]

Sharma S.K., Singla R., Sarda P., Et al., Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity, Clin Infect Dis, 50, pp. 833-839, (2010)

← 1 2 →